We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA ISSUES DRAFT GUIDANCE ON PMA MANUFACTURING REVIEW AND INSPECTIONS

FDA ISSUES DRAFT GUIDANCE ON PMA MANUFACTURING REVIEW AND INSPECTIONS

June 16, 2006

The FDA published draft guidance June 19 to assist devicemakers in preparing for FDA's review of their premarket approval (PMA) applications and for coordinating inspections for PMA supplements.

The guidance discusses:

The steps that will be taken by the Office of Compliance (OC) or the Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD) when they review the manufacturing section of a PMA; The administrative process for reviewing Quality System (QS) regulation information contained in a PMA and the time frames involved in each step; and How the inspection of a manufacturing facility fits into the approval process.

The "Guidance for Industry and Food and Drug Administration Staff; the Review and Inspection of Premarket Approval Application Manufacturing

Information and Operations," can be viewed at http://www.fda.gov/OHRMS/DOCKETS/98fr/06d-0063-gdl0001.pdf (http://www.fda.gov/OHRMS/DOCKETS/98fr/06d-0063-gdl0001.pdf).

KEYWORDS FDAnews Device Daily Bulletin

Upcoming Events

  • 08Sep

    Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

  • 15Sep

    Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis

  • 20Sep

    Building a World-Class Pharmaceutical Advertising and Promotion Review Program

  • 21Sep

    The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval

  • 22Sep

    FDA’s New Quality Management System Regulation: What the Proposed Harmonization with ISO 13485 Means for Devicemakers

  • 11Oct

    1st Annual Quality Management vSummit

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • Thermo Fisher Scientific Gets FDA Premarket Approval for Companion Diagnostic

  • MHRA Grants Conditional Authorization to Moderna’s Bivalent COVID-19 Booster Vaccine

  • Organogenesis Gets 510(k) Clearance to Expand PuraPly Portfolio

  • FDA Grants Priority Review to sNDA for Lynparza

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • New Menu Placeholder NavLink
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing